Cbdmd Stock Price, News & Analysis

cbdMD, Inc. (NYSE American: YCBD) is a North Carolina-based wellness company focused on hemp-derived cannabinoid products and related functional wellness brands. According to its SEC filings and company disclosures, cbdMD owns and operates nationally recognized cannabidiol (CBD) brands and complementary product lines that span human wellness, pet care, functional mushrooms, and hemp-derived THC beverages.

Core Business and Brands

cbdMD states that it owns and operates the CBD brands cbdMD and Paw CBD, the functional mushroom brand ATRx Labs, and the hemp-derived THC beverage line Herbal Oasis. The company describes itself as a leading and highly trusted CBD brand with a comprehensive line of U.S.-produced, THC-free CBD products and Farm Act or Farm Bill–compliant Delta-9 offerings. Its disclosures note that cbdMD products include dietary supplements and topical products based on hemp-derived cannabinoids such as CBD, CBG and CBN, offered in broad spectrum (with THC below the level of detection) and full spectrum formats within applicable legal limits.

The Paw CBD brand focuses on veterinarian-formulated CBD products for pets. Company materials highlight that Paw CBD products have undergone the National Animal Safety Council’s audit and meet its Quality Seal standard. The ATRx Labs brand features functional mushroom products positioned for areas such as focus, calm, immunity, digestive health, and cognitive and mood support. Herbal Oasis is described as a premium, THC-infused social seltzer that blends cannabinoids with nootropic mushrooms in an alcohol-free beverage aimed at providing a fast-acting, functional experience centered on presence and connection.

Product Categories and Formulations

In its registration statements and press releases, cbdMD explains that its cbdMD-branded line includes everyday and functional CBD products such as tinctures, gummies, topicals, capsules, drink mixers, and products formulated for sleep, focus, and calming support. The company notes that it uses hemp-derived cannabinoids sourced from hemp grown on farms in the United States, and that its broad spectrum formulations are designed to include CBD, CBG, and CBN while eliminating detectable THC using validated analytical methods. Its full spectrum and Delta-9 products are described as containing a variety of cannabinoids and terpenes while maintaining THC levels within the limits set in the 2018 Farm Act.

For Paw CBD, cbdMD highlights tinctures, chews, and topical products in varying strengths and formulas for pets. ATRx Labs offerings are described as functional mushroom supplements built around non-psychoactive dietary mushrooms. Herbal Oasis is characterized as a hemp-derived THC seltzer crafted to elevate social experiences, with wellness-forward ingredients and an alcohol-free formulation.

Distribution and Market Reach

Company filings and press releases state that cbdMD distributes its products through its own e-commerce websites, third-party e-commerce platforms, select distributors and marketing partners, as well as a variety of brick-and-mortar retailers. Disclosures also reference thousands of retail outlets that carry cbdMD’s products across the United States. The Herbal Oasis beverage brand has been described in recent news as expanding distribution through beverage distributors in multiple U.S. states, while cbdMD’s core CBD business continues to emphasize direct-to-consumer online sales alongside retail channels.

Corporate Structure and History

According to its SEC registration statements, cbdMD, Inc. is incorporated in North Carolina and maintains principal executive offices in Charlotte, North Carolina. The company traces its corporate history to an entity formed in March 2015 under the name Level Beauty Group, Inc., later renamed Level Brands, Inc., and ultimately cbdMD, Inc. effective May 1, 2019. Subsidiaries referenced in filings include CBD Industries LLC, Paw CBD, Inc., cbdMD Therapeutics LLC, and Proline Global, LLC, which house various operating activities, including science and research efforts and newer brands.

Strategic Focus and Capital Structure

Recent filings and news releases emphasize cbdMD’s focus on improving operating performance, strengthening its balance sheet, and maintaining compliance with NYSE American listing standards. The company has disclosed multiple preferred stock financings, including Series B and Series C Convertible Preferred Stock, as well as an equity line of credit arrangement registered on Form S-1 that allows for potential sales of common stock to an institutional investor. These capital measures are described as supporting working capital, liquidity, and growth initiatives for its consumer brands.

cbdMD has also reported regaining full compliance with NYSE American continued listing standards after resolving deficiencies related to certain equity thresholds. The company notes that it remains subject to ongoing exchange monitoring and highlights its intention to maintain financial discipline and governance.

Acquisitions and Brand Expansion

In an 8-K filed on January 13, 2026, cbdMD reported entering into an Asset Purchase Agreement to acquire substantially all of the assets of Gaia Botanicals, LLC, including the Bluebird Botanicals brand name, online CBD marketplace, related trademarks, inventory, and certain other assets and liabilities. The Bluebird Botanicals website is described as providing CBD education and information and offering CBD products such as gummies, oils, soft gels, creams, and pet products. A related press release characterizes Bluebird Botanicals as one of the longest-standing brands in the CBD industry with a loyal consumer following.

The asset purchase was structured as an equity transaction involving restricted shares of cbdMD common stock issued at closing and additional potential earnout shares, subject to conditions set out in the agreement. Company statements describe the acquisition as adding a differentiated portfolio of intellectual property, including patented-process technologies and regulatory compliance documentation, and as broadening product offerings and cross-brand distribution opportunities.

Regulatory and Scientific Orientation

Across its public communications, cbdMD underscores an emphasis on safety, quality, and scientific rigor in the production of its hemp-derived products. The company reports investing in GMP manufacturing, product testing, and compliance systems to align with applicable regulatory expectations. It also references cbdMD Therapeutics as a vehicle for research and development activities related to therapeutic applications of its existing and future products. Disclosures note that the company monitors evolving federal policy discussions around cannabinoids and hemp-derived products and views increasing regulatory clarity as a potential driver of further research and institutional interest in the category.

Stock Information

cbdMD’s common stock trades on the NYSE American under the ticker symbol YCBD. The company identifies itself in SEC filings as a smaller reporting company. Registration statements filed on Form S-1 and S-1/A describe offerings related to resale of common stock by selling shareholders, including shares issuable upon conversion of preferred stock and shares issuable under an equity line of credit arrangement.

Business Model Overview

Based on its SEC filings and press releases, cbdMD’s business model centers on developing, branding, and distributing hemp-derived cannabinoid products and related wellness offerings under multiple brands. Revenue is generated through direct-to-consumer e-commerce, sales to wholesalers and distributors, and placements in brick-and-mortar retail channels. The company positions its portfolio across human CBD wellness, pet CBD products, functional mushroom supplements, and hemp-derived THC beverages, and supplements this with scientific and regulatory work through cbdMD Therapeutics.

Risk and Going Concern Disclosure

In a press release summarizing its fiscal 2025 results, cbdMD noted that its audited consolidated financial statements included an audit opinion with an explanatory paragraph related to the company’s ability to continue as a going concern. This disclosure, referenced in its Annual Report on Form 10-K, signals that its independent registered public accounting firm identified conditions that raise substantial doubt about the company’s ability to continue as a going concern within a specified period, based on then-current financial information. Investors reviewing YCBD stock often consider such going concern language, along with the company’s capital-raising activities and operational performance, when evaluating risk.

Use Cases for Investors and Observers

For investors researching YCBD stock, cbdMD’s disclosures provide insight into a multi-brand wellness platform operating in the hemp-derived cannabinoid and functional mushroom space. Key elements include its emphasis on U.S.-grown hemp, THC-free and full spectrum formulations, veterinarian-formulated pet products, functional mushroom supplements, and a THC-infused social seltzer line. Regulatory filings detail its capital structure, financing transactions, and exchange-listing status, while news releases highlight operational trends, distribution expansion, and strategic acquisitions such as Bluebird Botanicals.